US 4,308,867 A · Two-member medicated device for rate-controlled administration of lipophilic pharmaceuticals

Abstract

The present specification describes a medicated device adapted for a single and rate-controlled rectal or vaginal administration to a mammal of a systemically active pharmaceutical (SAP). The device accomplishes drug administration at an essentially time-independent rate of dosage. Further, the device advantageously results in the substantial exhaustion of the SAP from the device at the conclusion of the single, acute use. The device comprises three elements: (A) an inert resilient support means contoured for easy vaginal or rectal insertion; (B) a first flexible polymer film layer affixed to the support means and containing the SAP dispersed therethrough, this first polymer film not being rate limiting as to the release of drug from the device; and (C) a second polymer film, laminated onto the first polymer film and providing a release rate therefrom of prostaglandin, which is rate limiting both as to the release of prostaglandin from the device and absorption rate by the rectal or vaginal tissues.

A medicated device adapted for a single and rate-controlled vaginal or rectal administration to a mammal of a SAP (systemically active pharmaceutical);

said administration being of a predetermined TD (therapeutic duration) of less than about 72 hours;
said administration resulting in the release of SAP from said device during the course of said administration at a predetermined, essentially time-independent RR (release rate) between about 1 .mu.g and 1 gm per hour;
and
said administration resulting in the exhaustion of said SAP from said device during the course of said treatment to the extent that the medicinal reuse of said device is essentially impossible;
which comprises:
(1) a flexible polymeric DBM (drug-bearing membrane), containing dissolved and suspended therethrough said SAP and being further characterized by:
(a) a D.sub.DBM (diffusion coefficient of said DBM with respect to said SAP) and an S.sub.DBM (solubility in said DBM of said SAP);
(b) an SA (surface area) of said DBM on the order of 10-50 cm.sup.2, being sufficiently great such that the RF (release flux of said SAP released from said device), which RF is the quotient which is said RR divided by said SA, is substantially less than the absorption rate per unit area of said SAP by the rectal or vaginal epithelial tissues of said mammal in contact with said device during said administration;
and
(c) an essentially uniform T.sub.DBM (thickness of said DBM) and a C.sub.DBM, (initial concentration of said SAP in said device), which C.sub.DBM is the quotient which is the amount of said SAP divided by the volume of said DBM;
(2) a flexible polymeric RCM (rate controlling membrane), being laminated onto a first surface of said DBM and being substantially coextensive therewith, being further characterized by:
(a) an S.sub.RCM (solubility in said RCM of said SAP) and an essentially uniform T.sub.RCM (thickness of said RCM);
and
(b) D.sub.RCM (diffusion coefficient of said RCM with respect to said SAP), such that the R.sub.RCM (resistance of said RCM), which R.sub.RCM is the quotient which is said T.sub.RCM divided by the product of (i) K (partition coefficient between said DBM and RCM), which is the quotient which is said S.sub.DBM divided by said S.sub.RCM and (ii) said D.sub.RCM, is at least very much greater than the R.sub.DBM (resistance of said DBM), which R.sub.DBM is the quotient which is said T.sub.DBM divided by said D.sub.DBM ;
and
(3) a physiologically inert, resilient, and water-insoluble support means, having the second surface of said DBM laminally affixed to at least a portion of the surface thereof;
being adapted, contoured, and dimensioned for accomodation of the entirety of said DBM on the surface thereof and for easy and comfortable rectal or vaginal insertion and withdrawal of said device;
being essentially non-absorptive of said SAP;
and being of substantially non-concave construction, whereby the surface of said device upon insertion is in essentially complete and intimate contact with rectal or vaginal epithelial tissues and associated secretions;
said device being further characterized by
(a) said T.sub.RCM being approximately
(D.sub.RCM S.sub.RCM)/RF (1)
wherein RF, D.sub.RCM and S.sub.RCM are as defined above;
(b) a T.sub.50, which is the time after TD for the RF to be reduced by 50 percent, being approximately
(1n2)[P/(1-P)](TD) (2)
wherein P is the ratio of the amount of SAP remaining in said device at TD to the initial amount of SAP in said device, said P being characterized by a preselected value less than about 0.42;
and wherein TD is as defined above;
(c) said T.sub.DBM being approximately
[P/(1-P)][(RF)(TD)/S.sub.DBM ]-T.sub.RCM /2K (3)
wherein K, TD, T.sub.RCM, RF, and P are as defined above;
and
(d) said C.sub.DBM being approximately
[(RF)(TD)]/[(1-P)T.sub.DBM ] (4)
wherein P, RF, TD, and T.sub.DBM are as defined above.

31 more elements

Two-member medicated device for rate-controlled administration of lipophilic pharmaceuticals

Life of this patent

Two-member medicated device for rate-controlled administration of lipophilic pharmaceuticals

Life of this patent

Abstract

Claims1